Cannabidiol Inhibits Tau Aggregation In Vitro

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Alzheimer's disease (AD) is characterized by tau protein accumulation, leading to neuronal damage and synaptic loss.
• Inhibiting tau aggregation is a primary therapeutic strategy for AD.
• Cannabidiol (CBD), derived from Cannabis sativa L., possesses neuroprotective and antioxidant properties.

Purpose of the Study:

• To investigate the potential of CBD as a therapeutic agent for Alzheimer's disease.
• To examine the effect of CBD on the aggregation of recombinant human tau protein (1N/4R isoform) in vitro and in silico.

Main Methods:

• Biochemical assays including Thioflavin T (ThT) fluorescence assay.
• Spectroscopic techniques such as circular dichroism (CD).
• Microscopy techniques like atomic force microscopy (AFM).
• Computational methods including molecular docking and Job's plot analysis.
• Biophysical techniques such as quenching assay.

Main Results:

• CBD significantly suppressed the formation of tau fibrils.
• CBD interacts with tau protein via spontaneous binding, with a 1:1 molecular ratio.
• The binding involves hydrogen bonds, Van der Waals forces, and hydrophobic interactions.
• CBD affects the lag phase of tau protein aggregation kinetics.

Conclusions:

• CBD demonstrates potent anti-aggregation effects on human tau protein.
• CBD shows potential as a natural therapeutic agent for Alzheimer's disease by targeting tau pathology.
• This study offers new insights into CBD-based strategies for tau therapy in AD.